KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2016 - 2026)

Supernus Pharmaceuticals has reported Cash & Equivalents over the past 15 years, most recently at $128.4 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 85.27% to $128.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $128.4 million through Dec 2025, up 85.27% year-over-year, with the annual reading at $128.4 million for FY2025, 85.27% up from the prior year.
  • Cash & Equivalents was $128.4 million for Q4 2025 at Supernus Pharmaceuticals, down from $151.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $255.6 million in Q1 2021 and troughed at $24.7 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $113.6 million (2022), against an average of $120.1 million.
  • Year-over-year, Cash & Equivalents tumbled 85.75% in 2023 and then surged 377.92% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $203.4 million in 2021, then crashed by 54.23% to $93.1 million in 2022, then dropped by 19.4% to $75.1 million in 2023, then dropped by 7.63% to $69.3 million in 2024, then skyrocketed by 85.27% to $128.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cash & Equivalents are $128.4 million (Q4 2025), $151.4 million (Q3 2025), and $144.7 million (Q2 2025).